Modern warfarin- dosing algorithms in patients with atrial fibrillation

Modern warfarin- dosing algorithms in patients with atrial fibrillation

Aim. Thromboembolic complications are the leading cause of mortality in patients with atrial fibrillation. In order to summarize and represent a modern view on the anticoagulation therapy with warfarin recent specialized literature was reviewed. It was found that warfarin therapy is characterized by...

Full description

Saved in:

Bibliographic Details
Main Authors:	M. Yu. Kolesnyk, Ya. M. Mykhaylovskyi
Format:	Article
Language:	English
Published:	Zaporizhzhia State Medical and Pharmaceutical University 2015-12-01
Series:	Zaporožskij Medicinskij Žurnal
Subjects:	Atrial Fibrillation Warfarin Therapeutics Pharmacogenetics Genetic Testing
Online Access:	http://zmj.zsmu.edu.ua/article/view/57033/54640
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of warfarin therapy in patients with atrial fibrillation using genotype-guided dosing method
by: M. Yu. Kolesnyk, et al.
Published: (2022-09-01)

The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin
by: I. Yu. Koroleva, et al.
Published: (2016-11-01)

Platelet and coagulation hemostasis status in patients with atrial fibrillation depending on warfarin dosing method
by: M. Yu. Kolesnyk, et al.
Published: (2022-12-01)

ANALYSIS OF DIRECT COSTS ASSOCIATED WITH THE USE OF WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2016-01-01)

TIME IN THERAPEUTIC RANGE (TTR) IN ATRIAL FIBRILLATION WITH WARFARIN THERAPY IN SEMARANG, INDONESIA
by: Della Dafina Sekarsari, et al.
Published: (2021-10-01)

SPECIAL CONSIDERATIONS REGARDING WARFARIN DOSE TITRATION IN PATIENTS WITH ATRIAL FIBRILLATION DEPENDING ON CLINICAL FACTORS
by: E. L. Artanova, et al.
Published: (2016-01-01)

Hypercoagulability in patients with atrial fibrillation and associated obesity: a way to hemorrhage or thromboembolia?
by: Yu. V. Kovbasniuk, et al.
Published: (2017-10-01)

Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy
by: E. S. Mazur, et al.
Published: (2021-11-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01)

Frequencies of polymorphisms in genes affecting the pharmacokinetics of warfarin in the Zaporizhzhia region
by: M. Yu. Kolesnik, et al.
Published: (2021-07-01)

COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE
by: L. E. Kuvshinova, et al.
Published: (2015-09-01)

Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation
by: Yu. P. Skirdenko, et al.
Published: (2020-05-01)

Health Care Resource Use and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Polypharmacy Patients With Obesity
by: Mark Alberts, et al.
Published: (2025-01-01)

Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy
by: D. A. Napalkov, et al.
Published: (2019-09-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-12-01)

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
by: L. Y. Koroleva, et al.
Published: (2015-09-01)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01)

ANTITHROMBOTIC THERAPY IN NONVALVULAR ATRIAL FIBRILLATION: PROBLEMS AND PROSPECTS
by: A. Y. Rychkov, et al.
Published: (2016-01-01)

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2015-09-01)

Anticoagulant Therapy in Difficult Patients with Atrial Fibrillation: When the Risks of Embolism and Bleeding Are Comparable
by: D. A. Napalkov, et al.
Published: (2018-11-01)

Recurrent bleeding during standard anticoagulant therapy in comorbid patients with atrial fibrillation: a clinical case report
by: A. A. Kudriavtseva, et al.
Published: (2023-07-01)

Contribution of anticoagulant therapy adherence to the risk of complications of atrial fibrillation
by: Yu. P. Skirdenko, et al.
Published: (2019-03-01)

Anticoagulation control for nonvalvular atrial fibrillation in a tertiary academic centre in Johannesburg
by: Vanessa Mogashoa, et al.
Published: (2024-10-01)

QUALITY OF LIFE AND ITS DYNAMICS IN PATIENTS WITH ATRIAL FIBRILLATION AFTER LEAVING THE INTERNATIONAL CLINICAL TRIAL
by: E. L. Artanova, et al.
Published: (2015-12-01)

Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease
by: N. A. Shatalova, et al.
Published: (2023-11-01)

Factors related to the choice of warfarin for treating newly diagnosed nonvalvular atrial fibrillation are associated with safety outcomes during anticoagulation: A new‐user, active‐comparator, retrospective cohort study
by: Yoshiko Takagi, et al.
Published: (2024-12-01)

POSSIBILITY OF NOVEL ORAL ANTICOAGULANTS USAGE DURING ABLATION IN ATRIAL FIBRILLATION
by: B. A. Tatarsky, et al.
Published: (2014-12-01)

PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: Yu. B. Belousov, et al.
Published: (2015-12-01)

Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran
by: N. A. Novikova, et al.
Published: (2021-05-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

The influence of clinical and genetic factors on the stability of warfarin’s anticoagulant effect in patients with atrial fibrillation
by: Ya. M. Mykhailovskyi
Published: (2022-06-01)

THE ENDOVASCULAR PREVENTION OF THROMBOEMBOLISM IN ATRIAL FIBRILLATION
by: Rami N. Al-Ayyubi, et al.
Published: (2018-12-01)

Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage
by: A. S. Gerasimenko, et al.
Published: (2021-05-01)

The prevalence of allelic variants of VKORC1, CYP2C9 and CYP4F2 genes in Zaporizhzhia region population
by: M. Yu. Kolesnik, et al.
Published: (2019-03-01)

ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01)

Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease
by: V. I. Petrov, et al.
Published: (2019-09-01)

Comparison between DOACs and warfarin for left atrial thrombus in atrial fibrillation patients
by: Akihiro Sunaga, et al.
Published: (2025-08-01)

Excessive Hypocoagulation in Therapy with Warfarin within Polypharmacy: Using online database Multi-Drug Interaction Checker and Graphic “Time-Effect-Drug Administration” to Eliminate Adverse Drug Event (Case Report)
by: G. S. Krasnov, et al.
Published: (2018-11-01)

Changes in prescribing antithrombotic therapy in patients with atrial fibrillation and myocardial infarction in 2016-2019
by: K. G. Pereverzeva, et al.
Published: (2020-08-01)

ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01)